Knee osteoarthritis (OA) is a degenerative joint disease that causes pain, stiffness, and swelling as the knee's cartilage gradually deteriorates. It can be divided into two categories, namely, primary and secondary. Primary has no known origin, while secondary is brought on by things like injuries or aberrant joint mechanics. It is most common in older persons. The symptoms include joint stiffness after rest. It usually gets worse with activity. Treatments range from conservative therapy to surgical alternatives for severe instances. Moreover, the rising prevalence of the condition is anticipated to positively impact the pipeline landscape for knee osteoarthritis drugs.
Major companies involved in the knee osteoarthritis treatment market include Paradigm Biopharmaceuticals Inc., Pacira Pharmaceuticals, Inc., and Novartis Pharmaceuticals among others.
Leading drugs currently under the pipeline include QUC398 and FX201, among others.
The increasing cases of knee osteoarthritis and the rising technological advancements are poised to positively influence the knee osteoarthritis pipeline landscape.
The Knee Osteoarthritis Drug Pipeline Insight Report by Expert Market Research gives comprehensive insights into knee osteoarthritis therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for knee osteoarthritis. The knee osteoarthritis report assessment includes the analysis of over 25 pipeline drugs and 10+ companies. The knee osteoarthritis pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from the condition, and alignment with knee osteoarthritis treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to knee osteoarthritis.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Inflammatory and chondrocyte activity drives bone remodeling and cartilage degradation in knee osteoarthritis (OA). In the condition, articular cartilage is eroded by enzymes that break down collagen and proteoglycans35. Osteophyte and cyst development result from sclerosis of the underlying bone. Even while chondrocytes make an initial attempt at repair, cartilage loss eventually surpasses these attempts. This process is facilitated by metabolic alterations, mechanical strain, and inflammation. All parts of the joint, including the synovium and subchondral bone, are impacted by osteoarthritis
Hyaluronic acid and other small molecules and polymers are frequently recommended for the treatment of osteoarthritis in the knee. NSAIDs and COX-2 inhibitors are examples of small molecules that are used to treat pain and inflammation. Polymers, more especially, hyaluronic acid are given through viscosupplementation to serve as a lubricant and shock absorber. Injections of HA have demonstrated efficacy in reducing pain and enhancing functionality. Compared to small compounds and HA, gene therapy, recombinant fusion proteins, monoclonal antibodies, and peptides are less well-established and less frequently employed in the regular treatment of osteoarthritis, despite their potential. Further, the rising focus on the development of knee osteoarthritis emerging drugs and the advances in the understanding of the molecular pathogenesis of the disease are expected to support the pipeline expansion in the coming years.
About 32.5 million persons in the US alone suffer with osteoarthritis, the most prevalent kind of arthritis. In 2020, around 595 million individuals worldwide or 7.6% of the world's population were living with osteoarthritis. With over 43% of those afflicted being 65 years of age or older, the prevalence rises with age. Women account for 62% of osteoarthritis cases, making them disproportionately afflicted. Ageing populations and rising obesity rates are among the causes contributing to the increased prevalence, which has serious negative effects on both health and the economy.
This section of the report covers the analysis of knee osteoarthritis drug candidates based on several segmentations including:
By Phase
By Drug Class
By Route of Administration
The report covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II covers a major share of the total clinical trials, with a substantial number of knee osteoarthritis drugs undergoing clinical development.
The drug molecule categories covered under knee osteoarthritis pipeline analysis include recombinant fusion proteins, small molecules, peptides, polymers, monoclonal antibodies and gene therapies, among others. The knee osteoarthritis report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for knee osteoarthritis.
The EMR report for the knee osteoarthritis drug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed knee osteoarthritis therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in knee osteoarthritis clinical trials:
Major drugs currently in the drug pipeline are as follows:
Novartis Pharmaceuticals is conducting a Phase IIa clinical trial to evaluate the efficacy, safety, and tolerability of QUC398, an investigational ADAMTS5 inhibitor, in patients with symptomatic knee osteoarthritis. The study aims to determine if QUC398 can alleviate knee pain and preserve cartilage. Participants will receive subcutaneous injections every four weeks over a 16-month period. Enrollment has concluded, and the trial is currently active but not recruiting new participants.
Pacira Pharmaceuticals is developing FX201, an innovative gene therapy designed to treat osteoarthritis of the knee. FX201 utilizes a helper-dependent adenovirus vector to deliver the interleukin-1 receptor antagonist (IL-1Ra) gene directly into the joint, aiming to provide long-term anti-inflammatory effects. A Phase 1 clinical trial is currently underway to evaluate the safety and tolerability of FX201 in patients aged 30 to 80 with painful knee osteoarthritis. The study involves single ascending doses, with participants monitored for adverse events and therapeutic outcomes over an extended period.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The Knee Osteoarthritis Drug Report provides a strategic overview of the latest and future landscape of treatments for knee osteoarthritis. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities within the knee osteoarthritis pipeline insights.
Upto 15% Off
USD
$1999 $1799
$3099 $2789
$4599 $3909
$5999 $5099
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share